Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7228805 | 0.90 | GGPS1 (0.51) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL9797098 | 0.85 | GGPS1 (0.56) | GGPS1FDPSDRD4DRD3GPR84 | |
| Hydrochloric Acid SCHEMBL5655467 | 0.84 | GGPS1 (0.55) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL7222910 | 0.82 | GGPS1 (0.50) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL3796430 | 0.82 | GGPS1 (0.50) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL12801878 | 0.82 | GGPS1 (0.50) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL10666089 | 0.82 | GGPS1 (0.50) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL7961082 | 0.80 | GGPS1 (0.52) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL7229130 | 0.79 | GGPS1 (0.48) | GGPS1FDPSDRD4DRD3GPR84 | |
| SCHEMBL29030813 | 0.78 | GGPS1 (0.47) | GGPS1FDPSDRD4DRD3GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104292267-A | Preparation method of 1-hydroxyl-2-(imidazo[1,2-A]pyridine-3-yl)ethane-1,1-bisphosphonic acid | BEIJING NOVA HOPE MEDICAL TECHNOLOGY CO LTD | 2015-01-21 | — | — | CN | claimed |
| EP-1351722-B1 | ENDOSSEOUS IMPLANT | UNIV GENEVE (CH) | 2006-07-05 | — | — | EP | claimed |
| CN-1705486-A | Bisphosphonates for the treatment of antheroscleorosis and devices comprising them | NOVARTIS AG (CH) | 2005-12-07 | — | — | CN | claimed |
| CN-1620300-A | Method of administering bisphosphonates | NOVARTIS AG (CH) | 2005-05-25 | — | — | CN | claimed |
| CN-1535152-A | Use of bisphosphonates for the treatment of pain | ��˹��ŵ�� | 2004-10-06 | — | — | CN | claimed |
| CN-1384749-A | Use of diphophonic acid in treatment of vasculogenesis | NOVARTIS AG (CH) | 2002-12-11 | — | — | CN | claimed |
| CN-119698412-A | 5-HT2A receptor agonist, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025021120-A1 | 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-104292267-A | Preparation method of 1-hydroxyl-2-(imidazo[1,2-A]pyridine-3-yl)ethane-1,1-bisphosphonic acid | BEIJING NOVA HOPE MEDICAL TECHNOLOGY CO LTD | 2015-01-21 | — | — | CN | disclosed |
| EP-2804636-A1 | BONE FILLER COMPOSITION | DePuy International Limited (GB) | 2014-11-26 | — | — | EP | disclosed |
| CN-101490055-B | Spirocyclic azaindole derivatives | GRUENENTHAL GMBH | 2013-10-16 | — | — | CN | disclosed |
| EP-2041142-B1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013108035-A1 | BONE FILLER COMPOSITION | DEPUY INTERNATIONAL LIMITED (GB) | 2013-07-25 | — | — | WO | disclosed |
| US-20020028240-A1 | Timed-release compression-coated solid composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2002-03-07 | — | — | US | disclosed |
| CN-1331598-A | Pharmaceutical composition for treating bone lesions of multiple myeloma | YAMAMOUCHI PHARMACEUTICAL CO L (JP) | 2002-01-16 | — | — | CN | disclosed |
| US-6174877-B1 | EXCELLANT BACTERICIDES, ORAL ABSORBABILITY AND STABILITY; IMPROVE THE STABILITY TO RENAL DEHYDROPEPTIDASE I (DHP-I); 2-(2-(N-HETEROCYCLIC-ETHYLTHIO-) DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5998390-A | Combination of bisphosphonate and tetracycline | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0876370-A1 | CARBAPENEM COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5652227-A | Inhibition of the degradation of connective tissue matrix protein components in mammals | TERONEN OLLI PEKKA (FI) | 1997-07-29 | — | — | US | disclosed |
| WO-1997025325-A1 | CARBAPENEM COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028240-A1 | Timed-release compression-coated solid composition for oral administration | CRH, HRH2, HES1 | GGPS1 2602/4885FDPS 2400/4885DRD4 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.